$4M Bet Your Competitors Are Making on Heart Care

IMC Board
Jan 28
12 min read

While pulsed field ablation (PFA) costs more per procedure, leading insurers are approving coverage because the complete treatment costs—from procedure through recovery—along with competitive positioning and member satisfaction gains outweigh the device premium. Waiting means losing market share to carriers who understand this calculation.

Key Takeaways

PFA device costs are 3-4x higher but total episode costs run 15-25% lower through reduced complications and shorter stays
Procedure times drop from 4+ hours to 2-3 hours, enabling 40-60% higher daily throughput
Six FDA-approved systems launched since December 2023 with 500,000+ global procedures completed
Medicare NTAP payments expire September 2027, forcing strategic coverage decisions now
Medicare Advantage plans using PFA access as Star Ratings differentiator while commercial carriers face adverse selection
Safety profile superior: near-zero esophageal injury risk, eliminated phrenic nerve damage
Prior authorization criteria designed for thermal ablation now obsolete
Atrial fibrillation patient population projected to double by 2030—from 6 million to 12 million Americans

Every insurance professional knows the challenge: balancing innovation access against cost containment. But what happens when restricting a premium-priced technology actually increases total costs while damaging competitive positioning?

Coverage Decision Is Reshaping Cardiac Care Competition

While you're reading this, hospitals are investing millions in PFA systems. Competing carriers have already approved coverage, and employer groups are asking why some plans don't offer "the safer heart procedure."

The coverage decisions happening now will impact market position, member satisfaction scores, and medical loss ratios through 2030 and beyond.

Market Reality Behind PFA Adoption

Let's start with the numbers that matter for insurance planning. The American Heart Association projects that 12 million Americans will have atrial fibrillation by 2030.

That's up from approximately 6 million today—a doubling of potential exposure. Atrial fibrillation is a gateway to the most expensive claims. Untreated atrial fibrillation increases stroke risk by 500%, triples heart failure probability, and doubles dementia likelihood. Each of these downstream consequences carries six-figure claim potential.

Current treatment economics show traditional thermal ablation as established technology with predictable costs and 4+ hour procedures. Meanwhile, pulsed field ablation carries 3-4x higher device costs but 2-3 hour procedures with measurably lower complication rates. And yet both receive the same Medicare reimbursement rate regardless of the technology used.

Here's what matters: hospitals are adopting PFA despite unfavorable reimbursement because operational gains overwhelm device costs. MelroseWakefield Hospital expects to double atrial fibrillation procedure volume within 12 months of PFA adoption.

Cleveland Clinic and Mayo Clinic have been using it for two years and continue expanding capacity. When hospitals can treat twice as many patients per day with better outcomes, utilization assumptions just became obsolete.

Total Cost Analysis that Changes Everything

Device cost is the distraction. Total episode cost is what impacts loss ratios and competitive positioning.

Dr. Laurence Conway, chief of cardiology at MelroseWakefield Hospital, explained the business case: "Even though the console and device [are] more expensive than traditional thermal ablation, it's going to be much more profitable because the volume is going to grow exponentially."

Standard thermal ablation episodes involve 4-6 hours procedure time with extended general anesthesia exposure. Add 1-2 day hospital stays, 2-5% serious complication rates requiring intervention, and 8-12% readmission rates within 30 days.

PFA episodes reduce procedure time to 2-3 hours with reduced anesthesia duration. Same-day or overnight discharge is increasingly common. Serious complication rates drop below 1%, and readmission rates fall to 4-6% within 30 days.

The math matters for total cost analysis. Shorter procedures mean lower facility fees even at identical reimbursement rates.

Reduced anesthesia time cuts pharmacological costs and physician time. Fewer complications eliminate five-figure complication management expenses.

Most significantly, avoiding one esophageal injury, one stroke, or one phrenic nerve paralysis pays for hundreds of incremental device costs. Most utilization management protocols don't account for this risk reduction yet.

Reimbursement Situation Through 2027 and What Comes After

Here's where strategic planning gets complicated. The Centers for Medicare & Medicaid Services (CMS) hasn't differentiated PFA reimbursement under Medicare's Physician Fee Schedule, creating identical payment rates regardless of energy source.

Medicare Fee-for-Service provides identical payment for PFA and thermal ablation. However, it offers New Technology Add-on Payments (NTAPs) for inpatient cases. These cover the lesser of 65% of technology costs or amounts exceeding standard Medicare diagnosis-related groups (DRGs) payment.

Medtronic PulseSelect has explicit NTAP approval. Other manufacturers' devices may qualify based on coding.

Medicare Advantage plans get no NTAP application, forcing plans to absorb full cost differentials. This creates Star Ratings opportunities through superior outcomes and improved member satisfaction scores with faster procedures.

Commercial payers similarly have no NTAP eligibility. Negotiated rates determine margin impact. Carriers face adverse selection risk if competitors cover while they restrict, but also gain premium positioning opportunities in the employer marketplace.

The critical date is September 30, 2027, when NTAP expires. By then, PFA will probably be the standard of care with robust outcomes data.

CMS will face pressure to either extend NTAP, create differentiated reimbursement, or leave providers absorbing costs on dominant technology. The question is what's the coverage posture when NTAP disappears, but clinical superiority is established?

Star Ratings, Member Satisfaction, and Market Positioning

For Medicare Advantage plans, PFA creates measurable competitive advantage. It directly impacts the metrics that CMS uses for Star Ratings.

Dr. Christopher DeSimone from Mayo Clinic emphasized the patient experience: "That makes things much more favorable for the patient and for the operator." Shorter procedures, reduced complications, and faster recovery translate directly into member satisfaction survey responses.

Star Ratings impact pathways include improving or maintaining physical health (outcomes measure), managing chronic conditions (atrial fibrillation management quality), rating of health care quality (member satisfaction), and customer service (access to advanced treatments). Leading Medicare Advantage plans are already marketing PFA network access in sales presentations.

They're positioning it alongside other advanced cardiac capabilities as proof of quality network construction. When one network can't offer PFA while competitors can, it's a clinical disadvantage as well as a sales disadvantage that resonates with employer groups.

Prior Authorization: Current Protocols Are Already Obsolete

Most carriers apply identical prior authorization criteria to all atrial fibrillation ablation procedures. That made sense when technology options were comparable, but it's indefensible now.

Prior authorization criteria for traditional thermal ablation typically require failed pharmacological therapy (two or more antiarrhythmic drugs), documented symptomatic atrial fibrillation, absence of contraindications, qualified electrophysiologist performing procedure, and appropriate facility certification. These criteria were designed when complication risk was the governing concern.

PFA's safety profile fundamentally changes the calculation. Dr. Tyler Taigen from the Cleveland Clinic said, "We don't have to worry about things that would really give us quite a bit of angst when we did these ablations before."

PFA targets only cardiac muscle cells while sparing surrounding tissue. It reduces esophageal injury risk from 0.1-0.25% to near-zero. It essentially eliminates phrenic nerve damage and dramatically reduces pulmonary vein stenosis.

Carriers are evaluating whether PFA's superior safety profile justifies different coverage criteria. Should patients qualify earlier in their disease progression? Should age restrictions be relaxed? Should comorbidity exclusions be reconsidered?

Maintaining identical criteria for technologies with materially different risk profiles creates coverage denial appeals, provider friction, and member complaints.

Network Contracting: New Opportunities Emerging

Hospital systems investing in PFA technology are looking for volume commitments to justify capital expenditure. This creates negotiating opportunities that most carriers haven't explored yet.

After implementing PFA, MelroseWakefield Hospital reported capturing referrals previously going to academic medical centers. The hospital is also attracting patients from competing community hospitals. This referral pattern shift matters for network strategy.

Centers of Excellence (COE) programs are emerging that combine volume commitments with case rate discounts. These programs typically include quality metrics tied to outcomes rather than just complications, bundled payment arrangements covering 90-day episodes, and preferred provider designation for employer groups.

Some carriers are exploring gain-sharing arrangements that involve shared savings from reduced complications, performance guarantees on readmission rates, and efficiency bonuses for procedure time improvements.

Data-sharing agreements are becoming more common, establishing real-time outcomes tracking, complication rate transparency, patient satisfaction metrics, and cost per successful ablation calculations.

Carriers are approaching high-volume electrophysiology programs now, before market dynamics shift leverage. Hospitals need volume to justify investment. Hospitals need volume to justify their PFA investment, while carriers need predictable costs and outcome guarantees, creating opportunity for beneficial partnerships.

Adverse Selection Trap

Let's explore a scenario worth modeling: one carrier maintains restrictive PFA coverage while competitors approve broad access; what will happen?

Employers with executives experiencing atrial fibrillation preferentially select the competitor's plan. Brokers recommend the competitor for groups prioritizing comprehensive cardiac coverage. Members needing atrial fibrillation treatment switch at open enrollment.

Device costs get saved. But members who value cardiac coverage and are probably higher users across multiple service categories get lost.

Cardiac patients are informed health care consumers who research treatment options. They specifically ask about PFA availability during plan selection. They correlate cardiac coverage quality with overall plan generosity.

They're also often higher-income employees in key employer groups. And they influence peer recommendations and employer decision-making.

Boston Scientific CEO Michael Mahoney reported strong, double-digit growth for Farapulse on its Q3 earnings call. The company has treated over 500,000 patients globally, and its technology is becoming the market standard faster than most cardiac innovations.

Treating PFA as optional coverage is like treating robotic surgery as optional in 2015. The market moved, and restrictive carriers found themselves defending indefensible positions.

Claims Data Patterns Worth Tracking Now

Insurance carriers are establishing PFA-specific tracking immediately even when current volume is low. Data being collected in 2026 will inform 2027-2028 strategy.

Utilization patterns to track include PFA procedures per 1,000 covered lives, age distribution of PFA vs. thermal ablation patients, and gender patterns as atrial fibrillation affects men and women differently. Track geographic concentration, which typically mirrors where electrophysiologists with PFA training practice.

Cost metrics should cover average allowed amount per procedure, facility vs. professional component breakdown, and anesthesia costs comparison. Include same-day discharge rate and readmission costs within 30, 60, 90 days.

Quality indicators to monitor include complication rates by facility, postprocedure emergency department visits, and secondary procedures required. Track member satisfaction scores and complaint and grievance patterns.

Provider patterns worth tracking are which electrophysiologists adopt PFA first, volume concentration by facility, and thermal to PFA conversion rates. Monitor new-to-practice vs. established physician adoption.

This data builds evidence for coverage policy updates, contract negotiations, and network adequacy assessments.

What Medical Policy Committees Are Asking Device Manufacturers

Six manufacturers now have FDA-approved PFA systems: Medtronic (two systems), Boston Scientific, Johnson & Johnson MedTech, Abbott, and Kardium. Forward-thinking carriers are engaging them directly.

Questions about clinical evidence include:

What are your published complication rates in U.S. commercial use?
How many procedures are needed before operator competency is established?
What's your postmarket surveillance revealing about long-term durability?
Do you have head-to-head comparison data vs. thermal ablation?

Questions about training and support include:

What's included in your training programs?
How do you credential operators?
What ongoing education do you provide?
How do you handle adverse event investigations?

Questions about economic data include:

What's your all-in cost per case including disposables?
What volume commitments reduce per-unit costs?
What's your pricing trajectory over the next 24 months?
How do you support outcomes research?

These conversations inform coverage criteria, network adequacy standards, and COE program design. Competitive carriers are already having them.

2027 Decision Point Worth Planning for Now

The looming deadline of September 30, 2027 isn't far away in insurance planning cycles. When NTAP expires, several scenarios are possible, each requiring different strategies.

Scenario 1: CMS Creates Differentiated Reimbursement

In this scenario, regulators acknowledge PFA's clinical advantages through the payment structure.

PFA receives higher payment rate reflecting superior outcomes and efficiency
This validates early adopters and accelerates market conversion
Strategy: align commercial coverage criteria with anticipated Medicare position and negotiate case rates that anticipate reimbursement changes

Scenario 2: NTAP Is Extended or Modified

CMS may choose to continue supporting the technology transition with adjusted terms.

CMS recognizes ongoing innovation in PFA technology and extends support, possibly with modified terms
Market dynamics continue current trajectory
Strategy: maintain flexibility in contracting and avoid locking into long-term case rates, assuming NTAP disappears

Scenario 3: NTAP Expires with No Reimbursement Change

The program could simply sunset without replacement, creating market pressure.

Hospitals absorb full cost differential
Market consolidation occurs as smaller programs exit PFA, making procedure availability a network adequacy issue
Strategy: identify which network hospitals have scale to sustain PFA programs and consider volume commitments to preserve access in key markets

Scenario 4: Clinical Evidence Forces Coverage Mandates

Outcomes data may become compelling enough to trigger regulatory requirements.

State or federal mandates require PFA coverage as the standard of care, based on outcomes data
Restrictive carriers face regulatory intervention
Strategy: establish liberal coverage now to avoid regulatory forcing and document outcomes to demonstrate responsible innovation adoption

Industry observers are monitoring CMS signals, congressional committee activity, and state insurance department positions on advanced cardiac technology coverage.

What Agents Need to Discuss PFA Confidently

Insurance agents need to understand PFA well enough to discuss it confidently with employer groups. Most agents know that atrial fibrillation is common, but can't articulate why PFA matters for plan selection.

When speaking with human resources (HR) benefit managers, agents could focus on how PFA represents clinical advancement that employees expect, its FDA approval and adoption by leading medical centers, and how coverage signals innovation commitment. When speaking with CFOs, they could emphasize that while the procedure itself costs more, total episode costs are competitive because of shorter hospital stays and fewer complications. When speaking with wellness directors, they could highlight that atrial fibrillation affects 1 in 4 adults over 40 and how superior treatment options reduce stroke risk, heart failure progression, and long-term disability costs.

Successful agents are accessing PFA fact sheets, coverage comparison tools, and member communication templates in order to demonstrate plan value.

Digital Marketing Opportunities Around Advanced Cardiac Care

Insurance carriers that don't create content around advanced cardiac care are losing search traffic and prospective members to competitors who are.

High-value content could include search-optimized articles on atrial fibrillation treatment coverage, health plan selection for heart rhythm disorders, and insurance benefits for cardiac care.

Member education videos could feature animated explanations of how PFA works and cardiologist interviews discussing treatment options. Employer resources could include benefit manager guides to cardiac coverage and cost comparison calculators.

Targeting keywords like "best health insurance for atrial fibrillation," "pulsed field ablation coverage," and "advanced cardiac care insurance" could capture high-value prospective members who are actively comparing plans.

Risk Adjustment and Star Ratings: Medicare Advantage Plan Advantage

For Medicare Advantage plans, PFA creates specific opportunities in risk adjustment and quality measurement. These directly impact revenue and member retention.

Atrial fibrillation patients typically have multiple hierarchical condition categories (HCCs). These include HCC 96: Specified Heart Arrhythmias (0.318 coefficient), often concurrent HCC 85: Congestive Heart Failure (0.323 coefficient), and frequently HCC 100: Ischemic Heart Disease (0.323 coefficient).

Successful atrial fibrillation management reduces progression to higher-cost conditions through better rhythm control. This means lower stroke incidence, avoiding the HCC 99-103 range, reduced heart failure exacerbations, decreased emergency utilization, and improved medication adherence.

Plans are modeling how PFA affects disease progression and subsequent HCC capture. Better outcomes today mean different morbidity patterns in 24-36 months.

PFA directly influences multiple Star Ratings measures. These include controlling high blood pressure as better cardiac output improves blood pressure control, medication adherence because better outcomes improve compliance, and plan all-cause readmissions as fewer complications mean fewer readmissions. It also demonstrates care coordination because it shows advanced treatment access.

In competitive markets, a 0.5 star improvement generates 5-7% membership growth. PFA won't move ratings alone, but it's part of a comprehensive quality strategy that compounds over time.

What Needs to Happen This Quarter

The insurance industry needs coordinated responses to PFA market dynamics. Here's what's happening in successful organizations over the next 90 days.

Insurance carriers are reviewing current atrial fibrillation ablation coverage criteria and obtaining clinical data from device manufacturers. Teams are interviewing medical directors at early-adopter plans, drafting updated coverage policies with PFA-specific criteria, and scheduling physician advisory panel discussions.

Network teams are surveying current electrophysiologist capacity and PFA adoption plans. They're identifying hospitals investing in PFA technology, initiating COE contract discussions, and developing quality metrics for atrial fibrillation procedure tracking. They're also creating PFA provider directories for member access.

Data analysts are establishing PFA-specific procedure code tracking and creating monthly dashboards for utilization trends. They're building cost comparison models such as PFA vs. thermal, flagging high-volume facilities for closer monitoring, and calculating current cost per successful ablation.

Finance teams are modeling per-member-per-month (PMPM) impact of various PFA adoption scenarios and forecasting utilization growth through 2030. They're assessing impact on medical loss ratio by product line, calculating risk adjustment implications for Medicare Advantage plans, and developing pricing assumptions for 2027 renewals.

Marketing and sales teams are creating PFA coverage fact sheets for distribution partners and developing employer presentation materials. They're updating plan comparison tools and decision guides, launching digital content campaigns on cardiac coverage, and adding PFA to network adequacy talking points.

Policy monitoring includes tracking CMS coverage determination processes and state insurance department positions. Teams are following medical society advocacy efforts, assessing regulatory risk of restrictive coverage, and developing positions for postNTAP environment.

Sources:

American Heart Association: Atrial Fibrillation
Cardiovascular Business: FDA approves Boston Scientific’s pulsed field ablation system for AFib
Cardiovascular Business: Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Cleveland Clinic: Pulsed-Field Ablation: A New, Highly Selective Catheter Ablation Method for Heart Arrhythmias
Fierce Biotech: Kardium grabs FDA approval for Globe pulsed field ablation catheter in afib
Mayo Clinic: Medical Professional Video Center: How a year's worth of experience of pulsed field ablation for AFib has...
MedTech Dive: Abbott receives FDA approval for Volt PFA system
Modern Healthcare: Hospitals are embracing pulsed field ablation. Here's why
Tufts Medicine: MelroseWakefield Hospital Successfully Performs Pulsed Field Atrial Fibrillation Ablation Procedure Using Intracardiac Echocardiography
U.S. Centers for Medicare & Medicaid Services (CMS): New Medical Services and New Technologies
U.S. Centers for Medicare & Medicaid Services (CMS): Part C and D Performance Data
U.S. Centers for Medicare & Medicaid Services (CMS): Risk Adjustment
U.S. Centers for Medicare & Medicaid Services (CMS): 2026 Medicare Advantage and Part D Star Ratings

Further Thoughts

Whether the industry realizes it or not, strategic choices about PFA are being made right now. Maintaining status quo coverage policies while the market transforms is a decision with competitive consequences.

Hospitals are investing in PFA because clinical and operational benefits overwhelm device costs. Leading carriers are approving coverage because restrictive policies create adverse selection risk. Members are researching treatment options and forming opinions about plan quality based on access to innovation.

The question isn't whether PFA becomes standard of care—clinical evidence and market adoption have already answered that. The question is whether organizations lead, follow, or get left behind in the transition.

Leading means proactive coverage, sophisticated contracting, and market positioning that demonstrates commitment to innovation. Following means reactive policy updates after competitors establish advantage. Getting left behind means fighting coverage denials, losing key accounts, and defending inferior network access.

Financial modeling can quantify the costs. Medical expertise can assess the evidence. Network teams can structure the contracts.

But strategic decisions need to happen about what kind of competitive position makes sense as cardiac care technology advances. Hospitals have already decided. Leading carriers are deciding now. What's the next move?